SEC Tracker
Get the app

Crescent Biopharma CBIO

Crescent Biopharma announces clinical updates.

Form
8-K
Filed
Importance
Routine
  1. Enrolled patients in CR-001 combination trials with chemo in ASCEND.
  2. Initiated ADC combination studies with CR-001.
  3. Planned Phase 1/2 APOLLO trial for CR-002 in Q4 2026.
  4. Expected data readouts in 2027 for multiple trials.

Written from the 8-K on EDGAR. Check the filing before you rely on it.

Open in the appGet the appView on EDGAR

Get an email when Crescent Biopharma files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. Omeros OMER public float $172M, Jun 30, 2025
  2. Lexicon Pharmaceuticals LXRX public float $170M, Jun 30, 2025
  3. XOMA Royalty XOMA public float $168M, Jun 30, 2025
  4. 4D Molecular Therapeutics FDMT public float $166M, Jun 30, 2025
  5. Editas Medicine EDIT public float $191M, Jun 30, 2025